Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Year: 2010
Type: article
Abstract: Limited evidence suggests that GLP-I may also preserve ventricular function and improve outcomes in human subjects with heart failure or myocardial infarction (11,12). [...] both exenatide and liraglutide reduce blood pressure, body weight, and plasma lipid profiles in subjects with type 2 diabetes (13), raising the hope that longterm treatment with these agents may reduce the incidence of cardiovascular events.\n However, two safety issues have been raised - pancreatitis and medullary carcinoma of the thyroid.
Source: Diabetes Care
DOI: 10.2337/dc09-1499
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: V Foundation for Cancer Research, Park Nicollet Foundation, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Roche, Sanofi, Celgene, Exelixis, Insulet Corporation, MannKind Corporation, ResMed, Eisai, Novo Nordisk, Plexxikon, National Institutes of Health, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases
OpenAlex ID: W2134760433
